HRS-4729 vs retatrutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline

HRS-4729

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 2 in Obesitypeptide
Weak signal

NCT06762600 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: March 2027 · NCT07690826 (registry estimate)

Reported efficacy

Adverse events (AEs) (Screening period up to day 43.): In the multiple-dose portion at Week 12, participants receiving multiple doses of 12 mg HRS-4729 achieved a mean weight loss of up to 16.0% from baseline, compared to 5.4% with placebo. HRS-4729 demonstrated linear pharmacokinetics with a half-life of approximately 4 to 5 days, supporting once-weekly dosing, and safety and tolerability consistent with GLP-1-based treatments. (not_applicable)

Result source: NCT06762600

retatrutide

Developed by Eli Lilly

Phase 3 in Obesitypeptide
Partial signal

NCT05882045 · Phase 3 · completed

The study was randomized, double-blind, and placebo-controlled, with 1,946 participants enrolled, and its primary endpoint was the clinical obesity outcome of percent change in body weight. The primary comparison favored retatrutide and met its primary endpoint per the sponsor's topline release (no p-value published), but no power calculation or planned enrollment target is provided in the available record, so the evidence is graded moderate rather than strong.

Next expected readout: November 2026 · NCT06662383 (registry estimate)

Reported efficacy

Percent Change from Baseline in Body Weight (Baseline, Week 80); Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (Baseline, Week 80): Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. (met)

Result source: NCT05929079

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHRS-4729retatrutide
Body weight, % change—Not reported-17.4% vs -1.6%−15.8 vs placebo12 mg (2 mg) · wk 24 · n 62NCT04881760
14 other results
  • -16.6% vs -1.6% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · primary NCT04881760
  • -18.3% vs -1.6% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · primary NCT04881760
  • -12% vs -1.6% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · primary NCT04881760
  • -13.8% vs -1.6% 4 mg · wk 24 · n 33 · Phase 2 · primary NCT04881760
  • -7.2% vs -1.6% 1 mg · wk 24 · n 69 · Phase 2 · primary NCT04881760
  • -24.2% vs -2.1% 12 mg (2 mg) · wk 48 · n 62 · Phase 2 · secondary NCT04881760
  • -21.7% vs -2.1% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -23.9% vs -2.1% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -16.3% vs -2.1% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -17.8% vs -2.1% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -8.7% vs -2.1% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • -20.8% vs -4% 12 mg · wk 80 · Phase 3 · primary NCT05929079
  • -19.1% vs -4% 9 mg · wk 80 · Phase 3 · primary NCT05929079
  • -12.7% vs -4% retatrutide 4 mg · wk 80 · Phase 3 · primary NCT05929079
Weight loss of 5% or more—Not reported100% vs 27%+73 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • 97% vs 26% 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • 100% vs 27% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 27% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 26% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 26% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 87% vs 27% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 97% vs 27% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 87% vs 26% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 94% vs 26% 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 64% vs 27% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • 59% vs 26% 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760
Weight loss of 10% or more—Not reported93% vs 9%+84 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • 90% vs 3% 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • 90% vs 9% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 91% vs 9% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 83% vs 3% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 94% vs 3% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 73% vs 9% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 76% vs 9% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 59% vs 3% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 72% vs 3% 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 27% vs 9% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • 25% vs 3% 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760
Waist circumference, change (cm)—Not reported-19.6 vs -2.6−17 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • -14.3 vs -2.6 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • -18.5 vs -2.6 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -18.5 vs -2.6 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -13.7 vs -2.6 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • -15.0 vs -2.6 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • -14.6 vs -2.6 4 mg (2 mg) · wk 48 · n 32 · Phase 2 · secondary NCT04881760
  • -14.9 vs -2.6 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -10.3 vs -2.6 4 mg (2 mg) · wk 24 · n 32 · Phase 2 · secondary NCT04881760
  • -12.6 vs -2.6 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • -6.5 vs -2.6 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • -5.4 vs -2.6 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760

Body weight, % change

HRS-4729
—Not reported
retatrutide
-17.4% vs -1.6%−15.8 vs placebo12 mg (2 mg) · wk 24 · n 62NCT04881760
14 other results
  • -16.6% vs -1.6% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · primary NCT04881760
  • -18.3% vs -1.6% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · primary NCT04881760
  • -12% vs -1.6% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · primary NCT04881760
  • -13.8% vs -1.6% 4 mg · wk 24 · n 33 · Phase 2 · primary NCT04881760
  • -7.2% vs -1.6% 1 mg · wk 24 · n 69 · Phase 2 · primary NCT04881760
  • -24.2% vs -2.1% 12 mg (2 mg) · wk 48 · n 62 · Phase 2 · secondary NCT04881760
  • -21.7% vs -2.1% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -23.9% vs -2.1% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -16.3% vs -2.1% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -17.8% vs -2.1% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -8.7% vs -2.1% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • -20.8% vs -4% 12 mg · wk 80 · Phase 3 · primary NCT05929079
  • -19.1% vs -4% 9 mg · wk 80 · Phase 3 · primary NCT05929079
  • -12.7% vs -4% retatrutide 4 mg · wk 80 · Phase 3 · primary NCT05929079

Weight loss of 5% or more

HRS-4729
—Not reported
retatrutide
100% vs 27%+73 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • 97% vs 26% 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • 100% vs 27% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 27% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 26% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 26% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 87% vs 27% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 97% vs 27% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 87% vs 26% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 94% vs 26% 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 64% vs 27% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • 59% vs 26% 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760

Weight loss of 10% or more

HRS-4729
—Not reported
retatrutide
93% vs 9%+84 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • 90% vs 3% 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • 90% vs 9% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 91% vs 9% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 83% vs 3% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 94% vs 3% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 73% vs 9% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 76% vs 9% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 59% vs 3% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 72% vs 3% 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 27% vs 9% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • 25% vs 3% 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760

Waist circumference, change (cm)

HRS-4729
—Not reported
retatrutide
-19.6 vs -2.6−17 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • -14.3 vs -2.6 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • -18.5 vs -2.6 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -18.5 vs -2.6 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -13.7 vs -2.6 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • -15.0 vs -2.6 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • -14.6 vs -2.6 4 mg (2 mg) · wk 48 · n 32 · Phase 2 · secondary NCT04881760
  • -14.9 vs -2.6 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -10.3 vs -2.6 4 mg (2 mg) · wk 24 · n 32 · Phase 2 · secondary NCT04881760
  • -12.6 vs -2.6 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • -6.5 vs -2.6 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • -5.4 vs -2.6 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-4729: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HRS-4729: 0 of 4 rows · retatrutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricretatrutide
Dropout rate
12.9%12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 5 more results
14.3%8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
17.1%8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
23.5%4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
21.2%4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
13%1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Discontinued due to AEs
3.2%12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 5 more results
2.9%8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
2.9%8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
0%4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
3%4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
1.4%1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Serious AEs
3.2%12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 5 more results
2.9%8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
5.7%8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
6.1%4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
0%4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
4.3%1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Most frequent reported AEs
12 mg (2 mg)
nausea 45.2% (placebo 11.4%)
decreased appetite 29% (placebo 8.6%)
covid-19 24.2% (placebo 20%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 5 more results
8 mg (2 mg)
diarrhoea 20% (placebo 11.4%)
covid-19 17.1% (placebo 20%)
nausea 17.1% (placebo 11.4%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
8 mg (4 mg)
nausea 60% (placebo 11.4%)
covid-19 31.4% (placebo 20%)
decreased appetite 31.4% (placebo 8.6%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
4 mg
nausea 36.4% (placebo 11.4%)
decreased appetite 24.2% (placebo 8.6%)
covid-19 18.2% (placebo 20%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
4 mg (2 mg)
decreased appetite 18.2% (placebo 8.6%)
nausea 18.2% (placebo 11.4%)
constipation 15.2% (placebo 2.9%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
1 mg
covid-19 18.8% (placebo 20%)
nausea 14.5% (placebo 11.4%)
decreased appetite 13% (placebo 8.6%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

retatrutide

Weight -17.39% (n=62) vs -1.55% (n=68) placebo @ 24wk12 mg (2 mg)
percent change · % of baseline
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 14 more results
-24.22% (n=62) vs -2.11% (n=68) placebo @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-20.8% vs -4% placebo @ 80wk12 mg
NCT05929079 · Phase 3 · sponsor-reported, not registry data
-19.1% vs -4% placebo @ 80wk9 mg
NCT05929079 · Phase 3 · sponsor-reported, not registry data
-16.64% (n=35) vs -1.55% (n=68) placebo @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-18.26% (n=35) vs -1.55% (n=68) placebo @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-21.72% (n=35) vs -2.11% (n=68) placebo @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-23.88% (n=35) vs -2.11% (n=68) placebo @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-12% (n=33) vs -1.55% (n=68) placebo @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-13.8% (n=33) vs -1.55% (n=68) placebo @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-16.32% (n=33) vs -2.11% (n=68) placebo @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-17.83% (n=33) vs -2.11% (n=68) placebo @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-12.7% vs -4% placebo @ 80wkretatrutide 4 mg
NCT05929079 · Phase 3 · sponsor-reported, not registry data
-7.18% (n=69) vs -1.55% (n=68) placebo @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-8.67% (n=69) vs -2.11% (n=68) placebo @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 5% 97% (n=62) vs 26% (n=68) placebo @ 24wk12 mg (2 mg)
responder rate · % of participants
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
100% (n=62) vs 27% (n=68) placebo @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
100% (n=35) vs 26% (n=68) placebo @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
100% (n=35) vs 26% (n=68) placebo @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
100% (n=35) vs 27% (n=68) placebo @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
100% (n=35) vs 27% (n=68) placebo @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
87% (n=33) vs 26% (n=68) placebo @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
94% (n=33) vs 26% (n=68) placebo @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
87% (n=33) vs 27% (n=68) placebo @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
97% (n=33) vs 27% (n=68) placebo @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
59% (n=69) vs 26% (n=68) placebo @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
64% (n=69) vs 27% (n=68) placebo @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 10% 90% (n=62) vs 3% (n=68) placebo @ 24wk12 mg (2 mg)
responder rate · % of participants
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
93% (n=62) vs 9% (n=68) placebo @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
83% (n=35) vs 3% (n=68) placebo @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
94% (n=35) vs 3% (n=68) placebo @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
90% (n=35) vs 9% (n=68) placebo @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
91% (n=35) vs 9% (n=68) placebo @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
59% (n=33) vs 3% (n=68) placebo @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
72% (n=33) vs 3% (n=68) placebo @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
73% (n=33) vs 9% (n=68) placebo @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
76% (n=33) vs 9% (n=68) placebo @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
25% (n=69) vs 3% (n=68) placebo @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
27% (n=69) vs 9% (n=68) placebo @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 15% 70% (n=62) vs 1% (n=68) placebo @ 24wk12 mg (2 mg)
responder rate · % of participants
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
83% (n=62) vs 2% (n=68) placebo @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
51% (n=35) vs 1% (n=68) placebo @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
68% (n=35) vs 1% (n=68) placebo @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
73% (n=35) vs 2% (n=68) placebo @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
77% (n=35) vs 2% (n=68) placebo @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
29% (n=33) vs 1% (n=68) placebo @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
44% (n=33) vs 1% (n=68) placebo @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
55% (n=33) vs 2% (n=68) placebo @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
64% (n=33) vs 2% (n=68) placebo @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
10% (n=69) vs 1% (n=68) placebo @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
16% (n=69) vs 2% (n=68) placebo @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Weight -18.53 vs -1.27 placebo kg @ 24wk12 mg (2 mg)
absolute change · kg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
-26.17 vs -1.84 placebo kg @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-17.7 vs -1.27 placebo kg @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-19.75 vs -1.27 placebo kg @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-23.52 vs -1.84 placebo kg @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-25.88 vs -1.84 placebo kg @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-12.59 vs -1.27 placebo kg @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-14.79 vs -1.27 placebo kg @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-17.32 vs -1.84 placebo kg @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-19.13 vs -1.84 placebo kg @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-7.72 vs -1.27 placebo kg @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-9.37 vs -1.84 placebo kg @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
BMI -6.44 vs -0.49 placebo kg @ 24wk12 mg (2 mg)
absolute change · kg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
-9.14 vs -0.72 placebo kg @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.15 vs -0.49 placebo kg @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.84 vs -0.49 placebo kg @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-8.12 vs -0.72 placebo kg @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-9.02 vs -0.72 placebo kg @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-4.47 vs -0.49 placebo kg @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-5.13 vs -0.49 placebo kg @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.14 vs -0.72 placebo kg @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.67 vs -0.72 placebo kg @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-2.64 vs -0.49 placebo kg @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-3.22 vs -0.72 placebo kg @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Waist Circumference Change -14.33 vs -2.6 placebo cm @ 24wk12 mg (2 mg)
absolute change · cm
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
-19.6 vs -2.64 placebo cm @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-13.74 vs -2.6 placebo cm @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-14.99 vs -2.6 placebo cm @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-18.53 vs -2.64 placebo cm @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-18.5 vs -2.64 placebo cm @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-10.33 vs -2.6 placebo cm @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-12.55 vs -2.6 placebo cm @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-14.58 vs -2.64 placebo cm @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-14.87 vs -2.64 placebo cm @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-5.43 vs -2.6 placebo cm @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.49 vs -2.64 placebo cm @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
WOMAC Pain -3.7 vs -2.1 placebo score @ 68wkretatrutide 12 mg
absolute change · score
NCT05931367 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-4 vs -2.1 placebo score @ 68wkretatrutide 9 mg
NCT05931367 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-4729's landscape · retatrutide's landscape